Breaking News Instant updates and real-time market news.

RLAY

Relay Therapeutics

$40.65 /

-0.67 (-1.62%)

06:07
08/10/20
08/10
06:07
08/10/20
06:07

Relay Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Relay Therapeutics with a Buy rating and $48 price target.

  • 16

    Jul

RLAY Relay Therapeutics
$40.65 /

-0.67 (-1.62%)

08/10/20 Cowen
Relay Therapeutics initiated with an Outperform at Cowen

TODAY'S FREE FLY STORIES

General news
FX Update: The dollar picked up » 03:45
04/13/21
04/13
03:45
04/13/21
03:45
$ECON

Economic Data

/

+

FX Update: The dollar…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
    General news
    Asian Market Update: » 01:55
    04/13/21
    04/13
    01:55
    04/13/21
    01:55
    $ECON

    Economic Data

    /

    +

    Asian Market Update:…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return in 9 minutes

    Get Free Trial

    ShowHide Related Items >><<
      General news
      U.S. CPI preview » 01:55
      04/13/21
      04/13
      01:55
      04/13/21
      01:55
      $ECON

      Economic Data

      /

      +

      U.S. CPI preview:…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
        Recommendations
        Reviews of Tela Bio's OviTex from two KOLs were positive, says Piper Sandler » 20:58
        04/12/21
        04/12
        20:58
        04/12/21
        20:58
        TELA

        Tela Bio

        $13.58 /

        + (+0.00%)

        Piper Sandler analyst…

        Piper Sandler analyst Matt O'Brien keeps his Overweight rating and $20 price target on Tela Bio after the company-hosted investor call featuring two key opinion leaders discussing their use of the company's OviTex in treating hernias. The clinicians used the product in hundreds of procedures ranging from simple cases to complex procedures, the analyst tells investors in a research note, adding that he was "struck by the enthusiasm" that both of the surgeons had for the product and the low recurrence rates in procedures using OviTex compared to competitive meshes.

        ShowHide Related Items >><<
        TELA Tela Bio
        $13.58 /

        + (+0.00%)

        TELA Tela Bio
        $13.58 /

        + (+0.00%)

        04/01/21 Piper Sandler
        Integra to benefit from FDA safety communication, says Piper Sandler
        03/25/21 Canaccord
        Tela Bio pieces in place for accelerating growth, says Canaccord
        01/14/21 Piper Sandler
        Piper says Tela Bio momentum looks 'healthy' despite 'slight' Q4 miss
        11/11/20 Piper Sandler
        Tela Bio price target raised to $20 from $17 at Piper Sandler
        TELA Tela Bio
        $13.58 /

        + (+0.00%)

        • 26
          Jun
        Recommendations
        New CEO at Amarin to facilitate continued growth, says Piper Sandler » 20:53
        04/12/21
        04/12
        20:53
        04/12/21
        20:53
        AMRN

        Amarin

        $5.85 /

        -0.09 (-1.52%)

        Piper Sandler analyst…

        Piper Sandler analyst Yasmeen Rahimi keeps her Overweight rating and $19 price target on Amarin after the company announced that Karim Mikhail would succeed John Thero as CEO later this year. The Street was surprised by the announcement, the analyst tells investors in a research note, but she believes that his deep commercial expertise will facilitate Amarin's continued growth, especially ahead of VAZKEPA's E.U. launch in Q3 of this year.

        ShowHide Related Items >><<
        AMRN Amarin
        $5.85 /

        -0.09 (-1.52%)

        AMRN Amarin
        $5.85 /

        -0.09 (-1.52%)

        04/06/21 Piper Sandler
        Amarin 'one step closer' to multi-billion opportunity, says Piper Sandler
        02/25/21 Piper Sandler
        Amarin to have strong execution year ahead, says Piper Sandler
        02/01/21 Piper Sandler
        Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
        01/29/21 Piper Sandler
        Amarin's EU approval 'guaranteed' after CHMP nod, says Piper Sandler
        AMRN Amarin
        $5.85 /

        -0.09 (-1.52%)

        AMRN Amarin
        $5.85 /

        -0.09 (-1.52%)

        AMRN Amarin
        $5.85 /

        -0.09 (-1.52%)

        AMRN Amarin
        $5.85 /

        -0.09 (-1.52%)

        Downgrade
        NorthWestern downgraded to Neutral from Outperform at Credit Suisse » 20:46
        04/12/21
        04/12
        20:46
        04/12/21
        20:46
        NWE

        NorthWestern

        $67.70 /

        +0.79 (+1.18%)

        Credit Suisse analyst…

        Credit Suisse analyst Michael Weinstein downgraded NorthWestern to Neutral from Outperform with a price target of $66, up from $60. The analyst says his rating change is driven by valuation following the recent period of outperformance in the stock.

        ShowHide Related Items >><<
        NWE NorthWestern
        $67.70 /

        +0.79 (+1.18%)

        NWE NorthWestern
        $67.70 /

        +0.79 (+1.18%)

        03/23/21 BofA
        NorthWestern upgraded to Neutral from Underperform at BofA
        12/04/20
        Fly Intel: Top five analyst initiations
        12/04/20 KeyBanc
        NorthWestern initiated with an Overweight at KeyBanc
        11/18/20 Barclays
        NorthWestern downgraded to Equal Weight from Overweight at Barclays
        NWE NorthWestern
        $67.70 /

        +0.79 (+1.18%)

        Upgrade
        MFA Financial upgraded to Outperform from Market Perform at Keefe Bruyette » 20:43
        04/12/21
        04/12
        20:43
        04/12/21
        20:43
        MFA

        MFA Financial

        $4.18 /

        +0.005 (+0.12%)

        Keefe Bruyette analyst…

        Keefe Bruyette analyst Bose George upgraded MFA Financial to Outperform from Market Perform with a $4.75 price target.

        ShowHide Related Items >><<
        MFA MFA Financial
        $4.18 /

        +0.005 (+0.12%)

        11/23/20 BTIG
        MFA Financial initiated with a Buy at BTIG
        08/24/20 JMP Securities
        MFA Financial upgraded to Outperform from Market Perform at JMP Securities
        08/24/20 JMP Securities
        MFA Financial upgraded to Outperform from Market Perform at JMP Securities
        04/13/20 JMP Securities
        MFA Financial downgraded to Market Perform from Outperform at JMP Securities
        MFA MFA Financial
        $4.18 /

        +0.005 (+0.12%)

        MFA MFA Financial
        $4.18 /

        +0.005 (+0.12%)

        Downgrade
        Cadence Bancorp downgraded to Sector Perform from Outperform at RBC Capital » 20:42
        04/12/21
        04/12
        20:42
        04/12/21
        20:42
        CADE

        Cadence Bancorp

        $22.41 /

        +0.92 (+4.28%)

        RBC Capital analyst Jon…

        RBC Capital analyst Jon Arfstrom downgraded Cadence Bancorp to Sector Perform from Outperform with a $25 price target.

        ShowHide Related Items >><<
        CADE Cadence Bancorp
        $22.41 /

        +0.92 (+4.28%)

        CADE Cadence Bancorp
        $22.41 /

        +0.92 (+4.28%)

        02/23/21 Stephens
        Stephens raises Regions price target to $23, sees possible deal for Cadence
        08/18/20 Keefe Bruyette
        Cadence Bancorp upgraded to Outperform from Market Perform at Keefe Bruyette
        08/14/20 Truist
        Cadence Bancorp upgraded to Buy from Hold at Truist
        08/14/20 Truist
        Cadence Bancorp upgraded to Buy from Hold at Truist
        CADE Cadence Bancorp
        $22.41 /

        +0.92 (+4.28%)

        CADE Cadence Bancorp
        $22.41 /

        +0.92 (+4.28%)

        Initiation
        Identiv initiated with a Buy at B. Riley » 20:29
        04/12/21
        04/12
        20:29
        04/12/21
        20:29
        INVE

        Identiv

        $11.75 /

        +0.25 (+2.17%)

        B. Riley analyst Craig…

        B. Riley analyst Craig Ellis initiated coverage of Identiv with a Buy rating and $21 price target.

        ShowHide Related Items >><<
        INVE Identiv
        $11.75 /

        +0.25 (+2.17%)

        INVE Identiv
        $11.75 /

        +0.25 (+2.17%)

        09/28/20 Northland
        Identiv benefitting as Apple supports NFC, says Northland
        09/22/20 Lake Street
        Identiv price target raised to $8 after management meeting at Lake Street
        INVE Identiv
        $11.75 /

        +0.25 (+2.17%)

        • 08
          Apr
        Hot Stocks
        Lyft CFO sells 15K shares of common stock » 20:27
        04/12/21
        04/12
        20:27
        04/12/21
        20:27
        LYFT

        Lyft

        $59.82 /

        -1.14 (-1.87%)

        In a regulatory filing,…

        In a regulatory filing, Lyft disclosed that its CFO Brian Roberts sold 15K shares of common stock on April 8th in a total transaction size of $919.9K, reducing his stake by about 1%.

        ShowHide Related Items >><<
        LYFT Lyft
        $59.82 /

        -1.14 (-1.87%)

        LYFT Lyft
        $59.82 /

        -1.14 (-1.87%)

        04/05/21 Evercore ISI
        Lyft assumed with an Outperform at Evercore ISI
        03/31/21 Wolfe Research
        Lyft assumed with a Peer Perform at Wolfe Research
        03/26/21
        Fly Intel: Top five analyst initiations
        03/26/21 Vertical Research
        Lyft initiated with a Buy at Vertical Research
        LYFT Lyft
        $59.82 /

        -1.14 (-1.87%)

        LYFT Lyft
        $59.82 /

        -1.14 (-1.87%)

        LYFT Lyft
        $59.82 /

        -1.14 (-1.87%)

        LYFT Lyft
        $59.82 /

        -1.14 (-1.87%)

        Upgrade
        FedEx upgraded to Overweight from Sector Weight at KeyBanc » 20:25
        04/12/21
        04/12
        20:25
        04/12/21
        20:25
        FDX

        FedEx

        $290.86 /

        +4.335 (+1.51%)

        KeyBanc analyst Todd…

        KeyBanc analyst Todd Fowler upgraded FedEx to Overweight from Sector Weight with a $350 price target. The analyst is citing the proprietary Online Parcel Index suggesting that B2C parcel volumes remained strong throughout Q1. Fowler adds that the positive trends around more resilient airfreight dynamics, leverage to improving global economic activity, and rational pricing dynamics should persist and "more than offset" any potential impact from a return to in-person shopping and service spending.

        ShowHide Related Items >><<
        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        04/12/21 KeyBanc
        FedEx upgraded to Overweight from Sector Weight at KeyBanc
        04/08/21 JPMorgan
        FedEx added to Analyst Focus List as value idea at JPMorgan
        03/26/21
        Fly Intel: Top five analyst initiations
        03/26/21 Vertical Research
        FedEx initiated with a Buy at Vertical Research
        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        Hot Stocks
        Innovent/Eli Lilly's phase 3 study of TYVYT in sqNSCLC saw OS improvement » 20:05
        04/12/21
        04/12
        20:05
        04/12/21
        20:05
        IVBXF

        Innovent Biologics

        $13.00 /

        + (+0.00%)

        , LLY

        Eli Lilly

        $181.76 /

        -2.71 (-1.47%)

        Innovent Biologics…

        Innovent Biologics (IVBXF) announced with Eli Lilly (LLY) that the results of the Phase 3 ORIENT-3 study were released today in an oral presentation at the American Association for Cancer Research Annual Meeting 2021. ORIENT-3 is a randomized, open-label, Phase 3 clinical trial evaluating TYVYT, or sintilimab injection, versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer, or sqNSCLC. A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled. Based on the primary analysis population, TYVYT demonstrated a statistically significant improvement in overall survival, or OS, compared to docetaxel, meeting the pre-specified primary endpoint. The median OS was 11.79 months for patients on the TYVYT arm and 8.25 months for those on the docetaxel arm. The median progression-free survival as assessed by investigators was 4.30 months versus 2.79 months, and the confirmed objective response rate was 25.5% versus 2.2%, respectively. Safety was consistent with previous studies of TYVYT, and no new safety signals were identified.

        ShowHide Related Items >><<
        LLY Eli Lilly
        $181.76 /

        -2.71 (-1.47%)

        IVBXF Innovent Biologics
        $13.00 /

        + (+0.00%)

        11/03/20 Daiwa
        Innovent Biologics initiated with a Buy at Daiwa
        07/08/20 JPMorgan
        Innovent Biologics downgraded to Neutral from Overweight at JPMorgan
        LLY Eli Lilly
        $181.76 /

        -2.71 (-1.47%)

        04/12/21 Benchmark
        Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
        04/06/21 JPMorgan
        JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
        03/24/21 BMO Capital
        AbCellera price target lowered to $59 from $61 at BMO Capital
        03/17/21 Mizuho
        AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
        LLY Eli Lilly
        $181.76 /

        -2.71 (-1.47%)

        LLY Eli Lilly
        $181.76 /

        -2.71 (-1.47%)

        LLY Eli Lilly
        $181.76 /

        -2.71 (-1.47%)

        LLY Eli Lilly
        $181.76 /

        -2.71 (-1.47%)

        Hot Stocks
        Opendoor Technologies up 1.5% afterhours after ARK Investment ETF trade update » 19:33
        04/12/21
        04/12
        19:33
        04/12/21
        19:33
        OPEN

        Opendoor Technologies

        $19.40 /

        -1.1 (-5.37%)

        Shares of Opendoor…

        Shares of Opendoor Technologies are up 1.5% afterhours at $19.70. In its daily evening update, ARK Investment Management disclosed a Buy of 633.4K shares of common stock.

        ShowHide Related Items >><<
        OPEN Opendoor Technologies
        $19.40 /

        -1.1 (-5.37%)

        OPEN Opendoor Technologies
        $19.40 /

        -1.1 (-5.37%)

        03/18/21
        Fly Intel: Top five analyst initiations
        03/18/21 Citi
        Opendoor Technologies initiated with a Buy at Citi
        03/05/21 Oppenheimer
        Opendoor Technologies price target lowered to $30 from $34 at Oppenheimer
        03/01/21 Credit Suisse
        Opendoor Technologies initiated with an Outperform at Credit Suisse
        OPEN Opendoor Technologies
        $19.40 /

        -1.1 (-5.37%)

        • 05
          Feb
        OPEN Opendoor Technologies
        $19.40 /

        -1.1 (-5.37%)

        OPEN Opendoor Technologies
        $19.40 /

        -1.1 (-5.37%)

        OPEN Opendoor Technologies
        $19.40 /

        -1.1 (-5.37%)

        Upgrade
        FedEx upgraded to Overweight from Sector Weight at KeyBanc » 19:25
        04/12/21
        04/12
        19:25
        04/12/21
        19:25
        FDX

        FedEx

        $290.86 /

        +4.335 (+1.51%)

        KeyBanc analyst Todd…

        KeyBanc analyst Todd Fowler upgraded FedEx to Overweight from Sector Weight.

        ShowHide Related Items >><<
        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        04/08/21 JPMorgan
        FedEx added to Analyst Focus List as value idea at JPMorgan
        03/26/21
        Fly Intel: Top five analyst initiations
        03/26/21 Vertical Research
        FedEx initiated with a Buy at Vertical Research
        03/22/21 Argus
        FedEx underperformance offers buying opportunity, says Argus
        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        FDX FedEx
        $290.86 /

        +4.335 (+1.51%)

        Hot Stocks
        Agilent CEO sells 15,095 shares of common stock » 19:20
        04/12/21
        04/12
        19:20
        04/12/21
        19:20
        A

        Agilent

        $131.25 /

        -0.635 (-0.48%)

        In a regulatory filing,…

        In a regulatory filing, Agilent disclosed that its CEO Michael McMullen sold 15,095 shares of common stock on April 8th in a total transaction size of $1.97M, reducing his stake by about 5%.

        ShowHide Related Items >><<
        A Agilent
        $131.25 /

        -0.635 (-0.48%)

        A Agilent
        $131.25 /

        -0.635 (-0.48%)

        03/18/21
        Fly Intel: Top five analyst upgrades
        03/18/21 Citi
        Agilent upgraded to Buy from Neutral at Citi
        03/18/21 Citi
        Agilent upgraded to Buy from Neutral at Citi
        02/17/21 Baird
        Agilent price target raised to $137 from $133 at Baird
        A Agilent
        $131.25 /

        -0.635 (-0.48%)

        A Agilent
        $131.25 /

        -0.635 (-0.48%)

        A Agilent
        $131.25 /

        -0.635 (-0.48%)

        Hot Stocks
        Mesa Air reports 28.1K block hours in March, down 15.9% from last year » 19:05
        04/12/21
        04/12
        19:05
        04/12/21
        19:05
        MESA

        Mesa Air

        $12.38 /

        -0.58 (-4.48%)

        Mesa Air Group reported…

        Mesa Air Group reported Mesa Airlines' operating performance for March 2021. Mesa Airlines reported 28,127 block hours in March 2021, a 15.9% drop from March 2020 "as a result of reduced schedules during the COVID-19 pandemic. The company also reported a controllable completion factor of 99.86 percent and 100 percent for its American and United operations, respectively. For Q2 of fiscal year 2021 ending March 31st, total block hours were 73,942 on 35,270 departures. These block hours are well below our guidance provided on our Q1 fiscal year 2021 Earnings Release. The reduced block hours and departures were the result of the mid-February major winter storm and subsequent Texas power outages impacting our major operations in both Dallas and Houston. During that period, we cancelled almost 1,300 flights representing close to 3,000 block hours while still incurring crew costs."

        ShowHide Related Items >><<
        MESA Mesa Air
        $12.38 /

        -0.58 (-4.48%)

        MESA Mesa Air
        $12.38 /

        -0.58 (-4.48%)

        03/04/21
        Fly Intel: Top five analyst downgrades
        03/04/21 Deutsche Bank
        Mesa Air downgraded to Hold after 100% rally at Deutsche Bank
        03/03/21 Deutsche Bank
        Mesa Air downgraded to Hold from Buy at Deutsche Bank
        02/17/21
        Fly Intel: Top five analyst upgrades
        MESA Mesa Air
        $12.38 /

        -0.58 (-4.48%)

        MESA Mesa Air
        $12.38 /

        -0.58 (-4.48%)

        MESA Mesa Air
        $12.38 /

        -0.58 (-4.48%)

        Initiation
        Tetra Tech initiated with a Hold at Vertical Research » 18:56
        04/12/21
        04/12
        18:56
        04/12/21
        18:56
        TTEK

        Tetra Tech

        $143.60 /

        +0.87 (+0.61%)

        Vertical Research analyst…

        Vertical Research analyst Michael Dudas initiated coverage of Tetra Tech with a Hold rating and $145 price target.

        ShowHide Related Items >><<
        TTEK Tetra Tech
        $143.60 /

        +0.87 (+0.61%)

        TTEK Tetra Tech
        $143.60 /

        +0.87 (+0.61%)

        02/01/21 Roth Capital
        Tetra Tech price target raised to $135 from $98 at Roth Capital
        01/15/21 Maxim
        Tetra Tech price target raised to $155 from $140 at Maxim
        11/12/20 Maxim
        Tetra Tech price target raised to $135 from $110 at Maxim
        11/09/20 Stifel
        Tetra Tech upgraded to Buy from Hold at Stifel
        TTEK Tetra Tech
        $143.60 /

        +0.87 (+0.61%)

        TTEK Tetra Tech
        $143.60 /

        +0.87 (+0.61%)

        Hot Stocks
        Air Canada enters into debt, equity financing agreement with Canadian government » 18:54
        04/12/21
        04/12
        18:54
        04/12/21
        18:54
        ACDVF

        Air Canada

        $21.53 /

        +0.1401 (+0.65%)

        Air Canada announced that…

        Air Canada announced that it has entered into a series of debt and equity financing agreements with the Government of Canada, which will allow Air Canada to access up to C$5.879B in liquidity through the Large Employer Emergency Financing Facility program. "Air Canada entered the pandemic more than a year ago with one of the global airline industry's strongest balance sheets relative to its size. We have since raised an additional $6.8 billion in liquidity from our own resources to sustain us through the pandemic, as air traffic ground to a virtual halt in Canada and internationally," said Michael Rousseau, President and Chief Executive Officer of Air Canada. "The additional liquidity program we are announcing today achieves several aligned objectives as it provides a significant layer of insurance for Air Canada, it enables us to better resolve customer refunds of non-refundable tickets, maintain our workforce and re-enter regional markets. Most importantly, this program provides additional liquidity, if required, to rebuild our business to the benefit of all stakeholders and to remain a significant contributor to the Canadian economy through its recovery and for the long term. As vaccine deployments ramp up, we continue to work with the Government of Canada on the evolution of safe and science-based test and quarantine relief measures with a view to safely restarting our sector. We know that Canadians are looking forward to re-connecting with friends and family and taking those long-awaited vacations and business trips and we will be ready to safely connect Canadians within Canada and Canada to the world," said Rousseau.

        ShowHide Related Items >><<
        ACDVF Air Canada
        $21.53 /

        +0.1401 (+0.65%)

        ACDVF Air Canada
        $21.53 /

        +0.1401 (+0.65%)

        04/09/21 CIBC
        Air Canada price target raised to C$34 from C$28 at CIBC
        04/08/21 National Bank
        Air Canada downgraded to Sector Perform from Outperform at National Bank
        03/16/21 TD Securities
        Air Canada downgraded to Hold from Buy at TD Securities
        03/12/21 Scotiabank
        Air Canada downgraded to Sector Perform from Outperform at Scotiabank
        ACDVF Air Canada
        $21.53 /

        +0.1401 (+0.65%)

        Hot Stocks
        FDA grants Akouos orphan drug designation in OTOF-mediated hearing loss » 18:54
        04/12/21
        04/12
        18:54
        04/12/21
        18:54
        AKUS

        Akouos

        $14.52 /

        +0.66 (+4.76%)

        On a post on the…

        On a post on the FDA's website, Akouos' treatment for otoferlin gene (OTOF)-mediated hearing loss was granted orphan drug designation. Reference Link

        ShowHide Related Items >><<
        AKUS Akouos
        $14.52 /

        +0.66 (+4.76%)

        AKUS Akouos
        $14.52 /

        +0.66 (+4.76%)

        04/05/21
        Akouos management to meet virtually with BTIG
        03/30/21 BofA
        Akouos downgraded to Neutral at BofA on OTOF IND filing delay
        03/30/21 BofA
        Akouos downgraded to Neutral from Buy at BofA
        08/13/20 Piper Sandler
        Akouos gearing up for 'busy' couple of years, says Piper Sandler
        AKUS Akouos
        $14.52 /

        +0.66 (+4.76%)

        • 26
          Jun
        Hot Stocks
        Air France-KLM, China Eastern Airlines extend scope of partnership » 18:41
        04/12/21
        04/12
        18:41
        04/12/21
        18:41
        AFLYY

        Air France-KLM

        $6.28 /

        -0.225 (-3.46%)

        In the context of the…

        In the context of the participation of China Eastern Airlines to the share capital increase of Air France-KLM, both airline groups have decided to extend the scope of their partnership through: an intensified commercial cooperation and an extended collaboration to noncommercial related activities, and; an increased footprint on the Beijing market, with the Paris-Beijing and Amsterdam-Beijing routes joining the current Joint Venture existing between Air France-KLM and China Eastern Airlines when conditions are satisfied.

        ShowHide Related Items >><<
        AFLYY Air France-KLM
        $6.28 /

        -0.225 (-3.46%)

        AFLYY Air France-KLM
        $6.28 /

        -0.225 (-3.46%)

        03/23/21 Citi
        Citi opens '90-day negative Catalyst Watc' on Air France-KLM
        03/15/21 UBS
        Air France-KLM price target raised to EUR 4.35 from EUR 4.15 at UBS
        02/22/21 Deutsche Bank
        Air France-KLM price target lowered to EUR 2.70 from EUR 3.50 at Deutsche Bank
        02/16/21 Bernstein
        Air France-KLM downgraded to Underperform from Market Perform at Bernstein
        AFLYY Air France-KLM
        $6.28 /

        -0.225 (-3.46%)

        Hot Stocks
        Vasta Platform CFO Clovis Poggetti Junior resigns, Bruno Giardino to succeed » 18:30
        04/12/21
        04/12
        18:30
        04/12/21
        18:30
        VSTA

        Vasta Platform

        $9.30 /

        +0.13 (+1.42%)

        Vasta Platform announced…

        Vasta Platform announced the resignation for personal reasons of Clovis Poggetti Junior as its CFO and investor relations officer and the appointment of Bruno Giardino to serve as the company's CFO and investor relations officer. Clovis Poggetti Junior will continue in the company until April 23, during which period he will transfer his activities to Bruno Giardino. Giardino joins the company after having served as the investor relations officer for the company's parent company, Cogna Educacao S.A., since March 2020.

        ShowHide Related Items >><<
        VSTA Vasta Platform
        $9.30 /

        +0.13 (+1.42%)

        VSTA Vasta Platform
        $9.30 /

        +0.13 (+1.42%)

        12/17/20 Scotiabank
        Vasta Platform initiated with an Outperform at Scotiabank
        08/25/20 UBS
        Vasta Platform initiated with a Buy at UBS
        08/25/20 Morgan Stanley
        Vasta Platform initiated with an Overweight at Morgan Stanley
        08/25/20 BofA
        Vasta Platform initiated with a Buy at BofA
        VSTA Vasta Platform
        $9.30 /

        +0.13 (+1.42%)

        • 31
          Jul
        Hot Stocks
        Safeguard Scientifics exits ownership of stake in Zipnosis » 18:29
        04/12/21
        04/12
        18:29
        04/12/21
        18:29
        SFE

        Safeguard Scientifics

        $6.45 /

        -0.155 (-2.35%)

        The company states:…

        The company states: "Safeguard Scientifics announced the exit of our ownership interest in Zipnosis. Safeguard received $3.3M of initial cash proceeds and a preferred equity interest in Bright Health Group, a national integrated healthcare company. The majority of the consideration we received in the transaction is reflected in this preferred equity interest. Additional cash proceeds may be received from the final determinations of net working capital and the resolution of various escrow contingencies. Safeguard will report a gain on the sale of the Zipnosis ownership interest for the quarter ended March 31, 2021, based on the total value received from the transaction."

        ShowHide Related Items >><<
        SFE Safeguard Scientifics
        $6.45 /

        -0.155 (-2.35%)

        On The Fly
        Fly Intel: After-Hours Movers » 18:25
        04/12/21
        04/12
        18:25
        04/12/21
        18:25
        MFNC

        Mackinac Financial

        $13.26 /

        -0.23 (-1.70%)

        , RILY

        B. Riley Financial

        $60.92 /

        -0.51 (-0.83%)

        , OTIC

        Otonomy

        $2.21 /

        -0.015 (-0.67%)

        , ZUO

        Zuora

        $16.48 /

        +0.045 (+0.27%)

        , SLP

        Simulations Plus

        $63.41 /

        +1.45 (+2.34%)

        , FBIO

        Fortress Biotech

        $5.47 /

        +0.02 (+0.37%)

        , NI

        NiSource

        $24.74 /

        +0.045 (+0.18%)

        , SCKT

        Socket Mobile

        $7.17 /

        -0.69 (-8.78%)

        , CHWY

        Chewy

        $84.02 /

        +0.03 (+0.04%)

        ShowHide Related Items >><<
        ZUO Zuora
        $16.48 /

        +0.045 (+0.27%)

        SLP Simulations Plus
        $63.41 /

        +1.45 (+2.34%)

        SCKT Socket Mobile
        $7.17 /

        -0.69 (-8.78%)

        RILY B. Riley Financial
        $60.92 /

        -0.51 (-0.83%)

        OTIC Otonomy
        $2.21 /

        -0.015 (-0.67%)

        NI NiSource
        $24.74 /

        +0.045 (+0.18%)

        MFNC Mackinac Financial
        $13.26 /

        -0.23 (-1.70%)

        FBIO Fortress Biotech
        $5.47 /

        +0.02 (+0.37%)

        CHWY Chewy
        $84.02 /

        +0.03 (+0.04%)

        MFNC Mackinac Financial
        $13.26 /

        -0.23 (-1.70%)

        RILY B. Riley Financial
        $60.92 /

        -0.51 (-0.83%)

        OTIC Otonomy
        $2.21 /

        -0.015 (-0.67%)

        02/22/21 Piper Sandler
        Otonomy price target lowered to $5 from $10 at Piper Sandler
        12/18/20 H.C. Wainwright
        Otonomy price target raised to $10 from $9 at H.C. Wainwright
        12/17/20 Piper Sandler
        Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
        11/04/20 Piper Sandler
        Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
        ZUO Zuora
        $16.48 /

        +0.045 (+0.27%)

        04/08/21 Berenberg
        Zuora initiated with a Buy at Berenberg
        02/24/21 Jefferies
        Zuora price target raised to $17 from $13 at Jefferies
        12/04/20 Canaccord
        Zuora risk/reward attractive into next year, says Canaccord
        06/29/20 Goldman Sachs
        Zuora price target raised to $11 from $10 at Goldman Sachs
        SLP Simulations Plus
        $63.41 /

        +1.45 (+2.34%)

        01/12/21
        Fly Intel: Top five analyst downgrades
        01/12/21 Craig-Hallum
        Simulations Plus downgraded to Hold from Buy at Craig-Hallum
        01/12/21 Oppenheimer
        Simulations Plus price target raised to $85 from $79 at Oppenheimer
        11/25/20 Taglich Brothers
        Simulations Plus upgraded to Buy from Speculative Buy at Taglich Brothers
        FBIO Fortress Biotech
        $5.47 /

        +0.02 (+0.37%)

        04/05/21 B. Riley
        Fortress Biotech price target raised to $9 from $8 at B. Riley
        02/17/21 Dawson James
        Fortress Biotech price target raised to $21 from $16 at Dawson James
        12/14/20 Benchmark
        Decision looms on Fortress' Caelum after partner Alexion bought, says Benchmark
        10/13/20 B. Riley
        Fortress Biotech weakness on Avenue CRL overblown, says B. Riley Securities
        NI NiSource
        $24.74 /

        +0.045 (+0.18%)

        03/22/21 UBS
        NiSource upgraded to Buy from Neutral at UBS
        01/28/21 Goldman Sachs
        NiSource downgraded to Neutral from Buy at Goldman Sachs
        11/18/20 Barclays
        NiSource upgraded to Overweight from Equal Weight at Barclays
        10/19/20 BofA
        NiSource upgraded to Buy from Neutral at BofA
        SCKT Socket Mobile
        $7.17 /

        -0.69 (-8.78%)

        CHWY Chewy
        $84.02 /

        +0.03 (+0.04%)

        04/05/21 Evercore ISI
        Chewy assumed with an Outperform at Evercore ISI
        03/31/21 Wolfe Research
        Chewy initiated with a Peer Perform at Wolfe Research
        03/31/21 Wedbush
        Chewy price target raised to $100 from $90 at Wedbush
        03/31/21 Jefferies
        Chewy price target raised to $105 from $100 at Jefferies
        ZUO Zuora
        $16.48 /

        +0.045 (+0.27%)

        SLP Simulations Plus
        $63.41 /

        +1.45 (+2.34%)

        SCKT Socket Mobile
        $7.17 /

        -0.69 (-8.78%)

        RILY B. Riley Financial
        $60.92 /

        -0.51 (-0.83%)

        OTIC Otonomy
        $2.21 /

        -0.015 (-0.67%)

        NI NiSource
        $24.74 /

        +0.045 (+0.18%)

        FBIO Fortress Biotech
        $5.47 /

        +0.02 (+0.37%)

        CHWY Chewy
        $84.02 /

        +0.03 (+0.04%)

        • 20
          Apr
        • 08
          Apr
        • 13
          Jan
        • 17
          Sep
        • 06
          Aug
        • 09
          Jul
        CHWY Chewy
        $84.02 /

        +0.03 (+0.04%)

        ZUO Zuora
        $16.48 /

        +0.045 (+0.27%)

        SCKT Socket Mobile
        $7.17 /

        -0.69 (-8.78%)

        RILY B. Riley Financial
        $60.92 /

        -0.51 (-0.83%)

        OTIC Otonomy
        $2.21 /

        -0.015 (-0.67%)

        CHWY Chewy
        $84.02 /

        +0.03 (+0.04%)

        ZUO Zuora
        $16.48 /

        +0.045 (+0.27%)

        SLP Simulations Plus
        $63.41 /

        +1.45 (+2.34%)

        FBIO Fortress Biotech
        $5.47 /

        +0.02 (+0.37%)

        CHWY Chewy
        $84.02 /

        +0.03 (+0.04%)

        Conference/Events
        Morgan Stanley IT hardware analyst to hold analyst/industry conference call » 18:09
        04/12/21
        04/12
        18:09
        04/12/21
        18:09
        DELL

        Dell Technologies

        $93.47 /

        -0.415 (-0.44%)

        IT Hardware Analyst…

        IT Hardware Analyst Huberty, along with Sam Burd, President of Client Solutions Group at Dell, discuss the future of work on an Analyst/Industry conference call.

        ShowHide Related Items >><<
        DELL Dell Technologies
        $93.47 /

        -0.415 (-0.44%)

        DELL Dell Technologies
        $93.47 /

        -0.415 (-0.44%)

        04/08/21 Morgan Stanley
        Dell Technologies price target raised to $107 from $98 at Morgan Stanley
        04/07/21 Deutsche Bank
        Dell Technologies price target raised to $100 from $94 at Deutsche Bank
        02/26/21 JPMorgan
        Dell Technologies price target raised to $98 from $90 at JPMorgan
        02/26/21 Credit Suisse
        Dell Technologies price target raised to $80 from $70 at Credit Suisse
        DELL Dell Technologies
        $93.47 /

        -0.415 (-0.44%)

        DELL Dell Technologies
        $93.47 /

        -0.415 (-0.44%)

        DELL Dell Technologies
        $93.47 /

        -0.415 (-0.44%)

        DELL Dell Technologies
        $93.47 /

        -0.415 (-0.44%)

        Conference/Events
        Morgan Stanley Euro capital goods analyst holds analyst/industry conference call » 18:07
        04/12/21
        04/12
        18:07
        04/12/21
        18:07

        European Capital Goods…

        European Capital Goods Analyst Carrier, along with Andrew Bright, Managing Director at Woodside Capital Partners, discuss a $500B investment opportunity in the US/European Electrical Grid on an Analyst/Industry conference call to be held on April 13 at 9 am.

        Get Full Fly Access

        Breaking market intelligence sent straight to you
        Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
        Up-to-date information on important industry events
        Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
        News focused on the companies in your portfolio
        Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.